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Abstract
OBJECTIVE: To investigate whether Jieduxiezhuo
decoction (JDXZD) can prevent serum uric acid ele-
vations in mice.
METHODS: Hyperuricemia in mice was induced by
intraperitoneally administering uric acid (250 mg/
kg). Concentrations of uric acid in serum were de-
termined using the uric acid enzyme method. Mice
were treated with JDXZD for 4 days before uric acid
was administered.
RESULTS: After intraperitoneal injection of uric ac-
id, serum uric acid concentrations in mice signifi-
cantly increased. However, the levels of uric acid in
groups pretreated with 16.25 or 4.06 g/kg of JDXZD
were significantly lower than those in the model
and normal groups.
CONCLUSION: Pretreatment with JDXZD slowed in-
creases in serum uric acid levels in mice intraperito-
neally administered uric acid.
© 2013 JTCM. All rights reserved.
Key words: Uric acid; Hyperuricemia; Pretreatment;
Jieduxiezhuo decoction
INTRODUCTION
High levels of serum uric acid in the body, called hyper-
uricemia, are caused by a variety of factors that increase
production of uric acid and decrease excretion of uric
acid, leading to concentrations of serum uric acid ex-
ceeding normal ranges. Generally, if the urine salt con-
centration is ≥417 µmol/L it should be considered hy-
peruricemia.1 Epidemiological data show that in recent
years, China's prevalence of hyperuricemia increased
significantly. For example, in Foshan, the prevalence is
22.6% for men and 11.6% for women.2 Hyperurice-
mia is an important biochemical basis for gout, is close-
ly related to cardiovascular diseases, chronic kidney dis-
eases and metabolic syndrome,3-8 and is harmful to hu-
man health as it is a serious metabolic disease.
Conventional medications for treatment of hyperurice-
mia, such as allopurinol and benzbromarone, are most-
ly used to inhibit the production of uric acid and pro-
mote the excretion of uric acid, and do have some clini-
cal effectiveness. However, these drugs have significant
side effects, such as liver and kidney function damage,
bone marrow suppression, gastrointestinal reactions,
and relapse after medication withdrawal. Because of
these adverse side effects, long-term administration of
these medications is not recommended. Compared
with conventional medicines, Traditional Chinese Med-
icine (TCM) was reported to be better in terms of safe-
ty, and other aspects, after long-term administration.9,10
With these studies in mind, the current study investi-
gated whether Jieduxiezhuo decoction (JDXZD) could
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reduce serum uric acid concentrations in model mice,
with the aim of providing experimental evidence for
the use of JDXZD in the treatment of hyperuricemia.
MATERIALS ANDMETHODS
Drugs and reagents
The Chinese herbal medicine used in the study includ-
ed Tuniuxi (Radix Achyranthis Sylvestris), Shancigu
(Pseudobulbus Cremastrae), Tufuling (Rhizoma Smilacis
Chinae), Qianniuzi (Semen Pharbitidis) and Puhuang
(Pollen Typhae), and were purchased from the Shanghai
Pudong New Area, Kang Qiao Herbal Pieces Factory
(Shanghai, China). Authentication of these herbs was
performed by Professor Xiling Li of the Botany Depart-
ment, Shanghai University of TCM. Voucher speci-
mens (Collection No. 2009-UA027, 2009-UA028,
2009-UA007, 2009-UA24, and 2009-UA382) were de-
posited in the Laboratory of Chinese Herbal Medicine
and Herbal Formula, Department of TCM, School of
Pharmacy, Shanghai University of TCM.
JDXZD was prepared from Shancigu (Pseudobulbus
Cremastrae), Tufuling (Rhizoma Smilacis Chinae), Qian-
niuzi (Semen Pharbitidis), Puhuang (Pollen Typhae)
(packaged) and Tuniuxi (Radix Achyranthis Sylvestris) in
the ratio of 1.5∶1.5∶1∶1∶1.5, respectively. A total of
260 g was used. One and a half liters of water was add-
ed, and the herbs were left to soak for 30 min before
they were boiled for 30 min and filtered while hot, and
the original decoction was obtained. Four times the vol-
ume of the decoction was added as water, and then
boiled and filtered. The decoction was concentrated to
200 mL and cooled, ready for use.
Reagents used were: uric acid (Sigma, St. Louis, MO,
USA; Batch No. 57K06701); allopurinol tablets (Xinyi
Vientiane, Shanghai, China; Batch No. 080801); uri-
case inhibitor oxonic acid potassium salt (OAPS,Sig-
ma, St. Louis, MO, USA; Lot No. 10726BH); and a
uric acid assay kit (Japan Shino-Test Corp., Tokyo, Ja-
pan; Batch No. C913).
Uric acid solution (25 mg/mL) was prepared by dissolv-
ing 1250 mg uric acid in a 50 mL flask with distilled
water to a concentration of 25 mg/mL, and then fro-
zen and set aside until required. OAPS solution
(25 mg/mL) was prepared by dissolving 1250 mg of
OAPS in a 50 mL flask with distilled water to a con-
centration of 25 mg/mL. Allopurinol solution I (4 mg/
mL) was prepared by crushing allopurinol (0.1 g/tab-
let) and adding 40 mg to a 10 mL flask with distilled
water to a concentration of 4 mg/mL. Allopurinol solu-
tion II (1.4 mg/mL) was prepared by crushing allopuri-
nol (0.1 g/tablet) and adding 14 mg to a 10 mL flask
with distilled water to a concentration of 1.4 mg/mL.
Experimental mice
The use of animals was approved by the Animal Ethi-
cal Committee of Shanghai University of Traditional
Chinese Medicine. One hundred Kunming male mice
(6 weeks old) of clean grade with a body weight (25±
2) g were supplied by the Experimental Animal Center
of Chinese Academy of Sciences (Certificate of confor-
mity: SCXK (Shanghai) 2007-0005).
Instruments
The following equipment was used: an analytical bal-
ance (AL104; Mettler Toledo, Zurich, Switzerland);
precision pipettes (200 µL; Gilson, Paris, France); an
automatic biochemical analyzer (7080; Hitachi, Tokyo,
Japan); and a centrifuge (Anting Scientific Instrument
Factory, Shanghai, China). An automatic biochemical
analyzer was used to measure the serum uric acid val-
ues by the uric acid enzymatic method.
Administration of JDXZD
The uric acid-induced hyperuricemia model mouse has
previously been reported,11,12 as have several studies ex-
amining uric acid levels in hyperuricemic mice.13-21 The
100 mice were randomly divided into five groups of
20: (a) a normal group; (b) a model group; (c) a
JDXZD high-dose group (16.25 g/kg); (d) a JDXZD
medium-dose group (4.06 g/kg); and (e) a JDXZD
low-dose group (1.02 g/kg). Mice were allowed to
adapt in a specific pathogen-free environment for 3
days before experiments. Mice in the normal and mod-
el groups were fed equal volumes (0.25 mL/10 g) of
distilled water. Mice in the JDXZD groups were fed
JDXZD liquid (0.25 mL/10 g) once a day for 3 days.
On the fourth day, mice in the normal and model
groups were given equal volumes (0.25 mL/10 g) of
distilled water, and mice in the JDXZD groups were
given JDXZD liquid (0.25 mL/10 g). Then, 60 min af-
ter the addition, mice in the normal group were inject-
ed intraperitoneally with equal volumes of distilled wa-
ter, and mice in the other groups were injected intraper-
itoneally with uric acid solution (0.1 mL/10 g). After
administration for 30 min, blood samples were collect-
ed from the orbital vein, and centrifuged at 8000 rpm
for 10 min to obtain the serum.
Statistical analysis
Data are expressed as mean± standard deviation. Data
were analyzed using SPSS 15.0 software (Chicago, IL,
USA). Differences between groups were compared us-
ing ANOVA with multiple comparisons (P<0.05 were
considered significant).
RESULTS
Serum uric acid levels in the model group were signifi-
cantly higher than those in the normal group (P<0.01),
suggesting the model was successfully established. Se-
rum uric acid levels in both the high- and medi-
um-dose groups were significantly lower than those in
the model group (P<0.01). Serum uric acid levels in
the low-dose group were lower than those in the model
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group, but the difference was not significant. This re-
sult indicates that JDXZD, with modest to high doses,
was able to hinder increases in serum uric acid. Howev-
er, the levels between the JDXZD-treated groups were
not significantly different (Figure 1).
DISCUSSION
Hyperuricemia is a common and serious risk to human
health. It is an important factor in gout, and increases
the risk of high blood pressure, coronary heart disease,
obesity, and insulin resistance. Therefore, it is impor-
tant to find effective medication for the treatment of
hyperuricemia.
Hyperuricemia is a term used in modern medicine,
with no corresponding name in TCM. According to
the characteristics and clinical manifestations of the
condition, and its etiology, pathology and other under-
standings in modern medicine, hyperuricemia can be
attributed to "phlegm coagulation", "blood stagna-
tion", "damp-toxin" and other areas in terms of TCM
theory.
JDXZD is derived from five Chinese herbal medicines.
They are Tuniuxi (Radix Achyranthis Sylvestris),
Shancigu (Pseudobulbus Cremastrae), Tufuling (Rhi-
zoma Smilacis Chinae), Qianniuzi (Semen Pharbitidis)
and Puhuang (Pollen Typhae). Tuniuxi (Radix Achyran-
this Sylvestris) can alleviate heat and clear toxicity, acti-
vate blood and resolve stagnation, induce diuresis and
drain dampness. It is therefore mainly used for the
treatment of syndromes caused by heat-toxin,
damp-toxin and blood stagnation. Shancigu (Pseudobul-
bus Cremastrae) can alleviate heat and clear toxins, cool
blood, remove stasis and dissipate carbuncles and nod-
ules. It is therefore mainly used for the treatment of
heat-toxin and blood stasis syndrome. Tufuling (Rhi-
zoma Smilacis Chinae) can remove dampness, relieve
toxicity and ease joint movement. It is therefore used
primarily for the treatment of damp-toxin and
heat-toxin syndrome. Qianniuzi (Semen Pharbitidis) is
able to discharge urine and stool to resolve phlegm, re-
move turbid-dampness, expel parasites and relieve stag-
nation. It is therefore mainly used for the clinical treat-
ment of syndromes caused by the retention of wa-
tery-damp, watery-phlegm and turbid-dampness,
damp-toxin and parasitic stagnation. Puhuang (Pollen
Typhae) moves blood and resolves stasis, and also stops
bleeding and induces dieresis. All components of
JDXZD combined purport to clear heat, toxicity, ex-
crete dampness, remove turbid-dampness, activate
blood and resolve stagnation. It is good for the treat-
ment of hyperuricemia.
In this study, serum uric acid levels in the JDXZD
high- and medium-dose groups were significantly low-
er (P<0.01) compared with the normal and model
groups. However, the levels between the JDXZD-treat-
ed groups showed no significant difference. The results
suggest that pretreatment of mice with JDXZD was
able to inhibit increases in levels induced by exogenous
uric acid without a dose response. Further study is re-
quired to get a better understanding of the mecha-
nisms underpinning the decoction's effect on hinder-
ing the elevation of blood uric acid levels.
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